Patent intelligence · US
US 2022348923
CA-IX APTAMERS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
CA-IX APTAMERS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
Patent details — US 2022348923
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 3, 2022
- Expiration
- Oct 29, 2042
- Applicant
- BRACCO IMAGING SPA [IT]
- CPC classes
- A61K 45/ 06 A I, A61K/4506
Quick answer
US 2022348923 (CA-IX APTAMERS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF) is held by BRACCO IMAGING SPA [IT]. Status: granted. Granted Nov 3, 2022. Expires Oct 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRACCO IMAGING SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 45/ 06 A I, A61K/4506
More from BRACCO IMAGING SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
CN 119365549
Fluorescent probe targeting CA-IX
granted -
CN 119343336
1, 4-bis-(2-hydroxy-benzyl)-1, 4, 7-triazacyclononane derivatives and similar compounds as ligands in iron (iii) complexes for use as MRI contrast agents
granted -
CN 119325492
Fluorescent probe targeting CA-IX
granted -
CN 118401500
Process for preparing mixtures of dimeric macrocyclic intermediates comprising gadolinium complexes
granted -
US 2024131199
PH RESPONSIVE CYANINE DYES AND CONJUGATES THEREOF
granted -
KR 20240034693
이량체 조영제의 제조
granted -
US 2023312523
NEAR-INFRARED CYANINE DYES AND CONJUGATES THEREOF
granted -
KR 20230116805
가도테리돌 제조를 위한 제조 방법
granted
Frequently asked questions
What is US patent 2022348923?
US 2022348923 (CA-IX APTAMERS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF) is held by BRACCO IMAGING SPA [IT]. Status: granted. Granted Nov 3, 2022. Expires Oct 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2022348923?
BRACCO IMAGING SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2022348923 expire?
Our index shows an expiration date of Oct 29, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.